Rafarma Pharmaceuticals, Inc. acquires Dartis D.O.O. and Ekopostopek D.O.O.

Rafarma (OTC: RAFA), a Wyoming Corporation, acquires Dartis D.O.O. and Ekopostopek D.O.O., Slovenian- based developers and manufacturers of Cosmetics, Therapy Creams, Gels, Sprays and vitality products.


Rafarma has acquired complete ownership of Dartis D.O.O. and Ekopostopek D.O.O., for Rafarma stock. This addition brings an entire new line of products to Rafarma as the company propels itself into new personal care channels including CBD-based products. The acquisition brings Rafarma the exclusive rights to distribute Dartis and Ekopostopek products in the U.S., Canada, Europe and Asia.


Srecko Bojt, Founder of Dartis and Ekopostopek, spoke of the acquisition in an interview: “We are so excited to have merged with Rafarma. The combined strengths of the merged companies will translate to increased development, production and sales well beyond Eastern Europe. We have many exciting products and announcements to come!”


Rafarma acquired Dartis and Ekopostopek for 10,500,000 preferred series “B” shares issued to the founding shareholder of the acquired companies, Srecko Bojt.


ABOUT RAFARMA PHARMACEUTICALS, INC.:

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.


Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

SOURCE: Rafarma Pharmaceuticals, Inc.